STLN Share Price Performance
US$0
-4.03 (-100.00%)
Price US$0
Fair ValueUS$7.75
Share Pricen/a
Narrative Update • Jul 21
The Oncology Institute, Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
STLN Community Narratives
AN
Fair Value
·Fair Value US$7.75 33.8% undervalued intrinsic discount
Florida And Nevada Expansions Will Strengthen Community Oncology Care
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value
·Fair Value US$7 26.7% undervalued intrinsic discount
Capitation And Pharmacy Pressures Will Test This Model Before Long Term Value Emerges
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$10 48.7% undervalued intrinsic discount
Value Based Oncology Expansion And AI Deployment Will Transform Long Term Earnings Power
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Value Based Oncology Expansion And AI Deployment Will Transform Long Term Earnings Power
The Oncology Institute is leaning into a model where insurers pay it to manage cancer care, and that shift could make revenue steadier while margins improve as newer contracts mature. Rapid pharmacy growth and plans to use AI to speed up billing and approvals could boost profits, but contract economics, tech disruptions, and funding needs remain key swing factors.Read more
AN
US$10
48.7% undervalued intrinsic discount
Fair Value
Profit Margin
0.37%
Future PE
333.36x
Price in 2029
US$12.26
Capitation And Pharmacy Pressures Will Test This Model Before Long Term Value Emerges
The Oncology Institute is scaling a Florida model that gets paid to manage cancer care, but it may take longer to show better profits as drug costs, payer terms, and new contract ramp-ups bite. See why its growing pharmacy business and expansion network could help over time, yet also create the biggest pressure points if reimbursement rules or utilization trends shift.Read more
AN
US$7
26.7% undervalued intrinsic discount
Fair Value
Profit Margin
0.36%
Future PE
239.91x
Price in 2029
US$8.58
Florida And Nevada Expansions Will Strengthen Community Oncology Care
The Oncology Institute is pushing into Florida and Nevada with a care model that gets paid for keeping patients healthier, which could bring in more patients and improve how efficiently the business runs. The upside depends on whether its fast expansion, pharmacy growth, and tech upgrades can outpace reimbursement changes and tougher competition.Read more
AN
US$7.75
33.8% undervalued intrinsic discount
Fair Value
Profit Margin
6.1%
Future PE
17.44x
Price in 2029
US$9.5
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
TOI: Index Additions And 2026 Guidance Will Support Bullish Repricing
Fair Value: US$10 48.7% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TOI: Index Additions And 2026 Guidance Will Support Future Upside Potential
Fair Value: US$7 26.7% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
TOI: Reaffirmed 2026 Revenue Outlook Will Support Higher Forward Earnings Power
Fair Value: US$7.75 33.8% undervalued intrinsic discount
4 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
The Oncology Institute, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 06, 2026
- -0.36
- 15.12%
- -6.66%
- -482.7%
About STLN
- Founded
- 2007
- Employees
- 641
- CEO
- WebsiteView website
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.
